Milestone Pharmaceuticals Inc. (MIST) Form 8-K — May 13, 2026

$MISTForm 8-KItems 2.02, 9.01Filed May 13, 2026, 7:23 AM ET0001104659-26-059780Original filing

Milestone Pharmaceuticals Inc. announced its first quarter 2026 financial results, reporting a net loss of $26.1 million or $0.20 per share. The company's cash, cash equivalents, and short-term investments increased to $184.2 million from $106.0 million in the previous quarter, providing runway into the second half of 2027. The commercial launch of CARDAMYST™ (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT) is gaining traction, with approximately 600 scripts filled for 560 patients through April.

Key figures

Revenue: 238
Cash Position: 184200

Price after filing

1 day: -5.2%7 days: -12.8%30 days: -26.2%

Close on the filing date to close N calendar days later (from $1.72). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.